Onyx seeks expedited FDA review of myeloma drug carfilzomib

09/28/2011 | Xconomy

Onyx Pharmaceuticals has asked the FDA for priority evaluation of carfilzomib, a treatment candidate for multiple myeloma. Clinical data show that the drug reduces tumor size in patients who have received at least two previous therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA